Current Atherosclerosis Reports

, Volume 8, Issue 4, pp 330–336 | Cite as

Intracranial atherosclerotic stroke: Specific focus on the metabolic syndrome and inflammation

  • Oh Young BangEmail author


Stroke is the second leading cause of mortality worldwide and is well suited for prevention because it has a high prevalence, high burden of economic cost, well-defined modifiable risk factors, and effective prevention measures. Atherosclerosis is one of the major mechanisms of ischemic stroke, but the apparent differences in risk factors for intra- and extracranial atherosclerosis are unclear and the mechanisms that underlie strokes in patients with intracranial atherosclerosis are not well known. Consequently, patients with intracranial stenosis receive the same treatment as those with carotid atherosclerosis. Several novel substances have emerged recently as risk factors for atherosclerosis. Specifically, it has recently been suggested that both the metabolic syndrome, which refers to a constellation of metabolic risk factors that are linked to insulin resistance, and vascular inflammation are associated with increased risk of coronary heart disease and stroke. The results of the studies reviewed here suggest that these factors play a differential role in the development of atherosclerotic stroke between the intra- and extracranial arterial systems.


Metabolic Syndrome Ischemic Stroke Arterioscler Thromb Vasc Biol Metabolic Risk Factor Insulin Resistance Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Zimmet P: Global and social implications of the diabetes epidemic. Nature 2001, 414:782–787.PubMedCrossRefGoogle Scholar
  2. 2.
    Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002, 106:3143–3421.Google Scholar
  3. 3.
    Sacco RL, Kargman DE, Gu Q, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995, 26:14–20.PubMedGoogle Scholar
  4. 4.
    Wityk RJ, Lehman D, Klag M, et al.: Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996, 27:1974–1980.PubMedGoogle Scholar
  5. 5.
    Wong KS, Huang YN, Gao S, et al.: Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998, 50:812–813.PubMedGoogle Scholar
  6. 6.
    Moossy J: Morphology, sites and epidemiology of cerebral atherosclerosis. Res Publ Assoc Res Nerv Ment Dis 1966, 41:1–22.PubMedGoogle Scholar
  7. 7.
    Mitchell JR, Schwartz CJ: Relationship between arterial disease in different sites. A study of the aorta and coronary, carotid, and iliac arteries. BMJ 1962, 5288:1293–1301.CrossRefGoogle Scholar
  8. 8.
    Bang OY, Lee PH, Yoon SR, et al.: Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis. J Neurol Neurosurg Psychiatry 2005, 76:1128–1134.PubMedCrossRefGoogle Scholar
  9. 9.
    Akins PT, Pilgram TK, Cross DT 3rd, Moran CJ: Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 1998, 29:433–438.PubMedGoogle Scholar
  10. 10.
    Tanimoto S, Ikari Y, Tanabe K, et al.: Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population. Stroke 2005, 36:2094–2098.PubMedCrossRefGoogle Scholar
  11. 11.
    Shin DH, Lee PH, Bang OY: Mechanisms of recurrence in subtypes of ischemic stroke: a hospital-based follow-up study. Arch Neurol 2005, 62:1232–1237.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee PH, Oh SH, Bang OY, et al.: Infarct patterns in atherosclerotic middle cerebral artery versus internal carotid artery disease. Neurology 2004, 62:1291–1296.PubMedGoogle Scholar
  13. 13.
    Lammie GA, Sandercock PA, Dennis MS: Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke 1999, 30:1319–1325.PubMedGoogle Scholar
  14. 14.
    Schumacher HC, Tanji K, Mangla S, et al.: Histopathological evaluation of middle cerebral artery after percutaneous intracranial transluminal angioplasty. Stroke 2003, 34:e170–173PubMedCrossRefGoogle Scholar
  15. 15.
    Gorelick PB, Caplan LR, Hier DB, et al.: Racial differences in the distribution of anterior circulation occlusive disease. Neurology 1984, 34:54–59.PubMedGoogle Scholar
  16. 16.
    Caplan LR, Gorelick PB, Hier DB: Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986, 17:648–655.PubMedGoogle Scholar
  17. 17.
    Yasaka M, Yamaguchi T, Shichiri M: Distribution of atherosclerosis and risk factors in atherothrombotic occlusion. Stroke 1993, 24:206–211.PubMedGoogle Scholar
  18. 18.
    White H, Boden-Albala B, Wang C, et al.: Ischemic stroke subtype incidence among whites, blacks, and Hispanics: the Northern Manhattan Study. Circulation 2005, 111:1327–1331.PubMedCrossRefGoogle Scholar
  19. 19.
    Bang OY, Kim JW, Lee JH, et al.: Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology 2005, 65:296–298.PubMedCrossRefGoogle Scholar
  20. 20.
    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabetes Med 1998, 15:539–553.CrossRefGoogle Scholar
  21. 21.
    Rowley K, O’Dea K, Best JD: Association of albuminuria and the metabolic syndrome. Curr Diab Rep 2003, 3:80–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365:1415–1428.PubMedCrossRefGoogle Scholar
  23. 23.
    Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144:537–547.PubMedGoogle Scholar
  24. 24.
    Tracy RP, Lemaitre RN, Psaty BM, et al.: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997, 17:1121–1127.PubMedGoogle Scholar
  25. 25.
    Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.PubMedCrossRefGoogle Scholar
  26. 26.
    Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.PubMedCrossRefGoogle Scholar
  27. 27.
    Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.PubMedCrossRefGoogle Scholar
  28. 28.
    Pyorala M, Miettinen H, Halonen P, et al.: Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000, 20:538–544.PubMedGoogle Scholar
  29. 29.
    Kawamoto R, Tomita H, Oka Y, Kodama A: Metabolic syndrome as a predictor of ischemic stroke in elderly persons. Intern Med 2005, 44:922–927.PubMedCrossRefGoogle Scholar
  30. 30.
    Milionis HJ, Rizos E, Goudevenos J, et al.: Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005, 36:1372–1376.PubMedCrossRefGoogle Scholar
  31. 31.
    Rost NS, Wolf PA, Kase CS, et al.: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001, 32:2575–2579.PubMedGoogle Scholar
  32. 32.
    Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391–397.PubMedCrossRefGoogle Scholar
  33. 33.
    Vikram NK, Misra A, Dwivedi M, et al.: Correlations of C-reactive protein levels with anthropometric profile, percentage of body fat and lipids in healthy adolescents and young adults in urban North India. Atherosclerosis 2003, 168:305–313.PubMedCrossRefGoogle Scholar
  34. 34.
    Rutter MK, Meigs JB, Sullivan LM, et al.: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110:380–385.PubMedCrossRefGoogle Scholar
  35. 35.
    Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414–419.PubMedCrossRefGoogle Scholar
  36. 36.
    Sakkinen PA, Wahl P, Cushman M, et al.: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000, 152:897–907.PubMedCrossRefGoogle Scholar
  37. 37.
    Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840–844.PubMedGoogle Scholar
  38. 38.
    Lee KU: Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract 2001, 54(Suppl 2):S29-S33.PubMedCrossRefGoogle Scholar
  39. 39.
    Ford ES, Mokdad AH, Giles WH, Brown DW: The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003, 52:2346–2352.PubMedCrossRefGoogle Scholar
  40. 40.
    D’Armiento FP, Bianchi A, de Nigris F, et al.: Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke 2001, 32:2472–2480.PubMedGoogle Scholar
  41. 41.
    Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: the atherosclerosis and insulin resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000, 20:2140–2147.PubMedGoogle Scholar
  42. 42.
    Davis PH, Dawson JD, Riley WA, Lauer RM: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 2001, 104:2815–2819.PubMedGoogle Scholar
  43. 43.
    Urbina EM, Srinivasan SR, Tang R, et al.: Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). Am J Cardiol 2002, 90:953–958.PubMedCrossRefGoogle Scholar
  44. 44.
    Raitakari OT, Juonala M, Kahonen M, et al.: Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003, 290:2277–2283.PubMedCrossRefGoogle Scholar
  45. 45.
    Davies MJ, Richardson PD, Woolf N, et al.: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage and smooth muscle content. Br Heart J 1993, 69:377–381.PubMedGoogle Scholar
  46. 46.
    Liuzzo G, Biasucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994, 331:417–424.PubMedCrossRefGoogle Scholar
  47. 47.
    Danesh J, Whincup P, Walker M, et al.: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199–204.PubMedCrossRefGoogle Scholar
  48. 48.
    Iglseder B, Mackevics V, Stadlmayer A, et al.: Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke 2005, 36:2577–2582.PubMedCrossRefGoogle Scholar
  49. 49.
    Hsia J, Bittner V, Tripputi M, Howard BV: Metabolic syndrome and coronary angiographic disease progression: the Women’s Angiographic Vitamin & Estrogen Trial. Am Heart J 2003, 146:439–445.PubMedCrossRefGoogle Scholar
  50. 50.
    Mellen PB, Cefalu WT, Herrington DM: Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2006, 26:189–193.PubMedCrossRefGoogle Scholar
  51. 51.
    Burke AP, Tracy RP, Kolodgie F, et al.: Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002, 105:2019–2023.PubMedCrossRefGoogle Scholar
  52. 52.
    O’Rourke M: Mechanical principles in arterial disease. Hypertension 1995, 26:2–9.PubMedGoogle Scholar
  53. 53.
    Burke AP, Kolodgie FD, Farb A, et al.: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001, 103:934–940.PubMedGoogle Scholar
  54. 54.
    Whincup PH, Gilg JA, Donald AE, et al.: Arterial distensibility in adolescents: the influence of adiposity, the metabolic syndrome, and classic risk factors. Circulation 2005, 112:1789–1797.PubMedCrossRefGoogle Scholar
  55. 55.
    Salomaa V, Riley W, Kark JD, et al.: Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC Study: Atherosclerosis Risk in Communities Study. Circulation 1995, 91:1432–1443.PubMedGoogle Scholar
  56. 56.
    Giltay EJ, Lambert J, Elbers JM, et al.: Arterial compliance and distensibility are modulated by body composition in both men and women but by insulin sensitivity only in women. Diabetologia 1999, 42:214–221.PubMedCrossRefGoogle Scholar
  57. 57.
    Tkac I, Troscak M, Javorsky M, et al.: Increased intracranial arterial resistance in patients with type 2 diabetes mellitus. Wien Klin Wochenschr 2001, 113:870–873.PubMedGoogle Scholar
  58. 58.
    Shahar E, Chambless LE, Rosamond WD, et al.: Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003, 34:623–631.PubMedCrossRefGoogle Scholar
  59. 59.
    Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16:442–443.PubMedCrossRefGoogle Scholar
  60. 60.
    Einhorn D, Reaven GM, Cobin RH, et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9:237–252.PubMedGoogle Scholar
  61. 61.
    Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749.PubMedCrossRefGoogle Scholar
  62. 62.
    Wong ND, Pio JR, Franklin SS, et al.: Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003, 91:1421–1426.PubMedCrossRefGoogle Scholar
  63. 63.
    Pearson TA, Blair SN, Daniels SR, et al.: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388–391.PubMedCrossRefGoogle Scholar
  64. 64.
    Rothwell PM: Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. Cerebrovasc Dis 2005, 20(Suppl 1):24–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Di Napoli M, Papa F: Inflammation, statins, and outcome after ischemic stroke. Stroke 2001, 32:2446–2447.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of Neurology, Stroke and Cerebrovascular Center, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations